PL3426232T3 - Wielowarstwowa tabletka mazindol IR/SR i jej zastosowanie w leczeniu zespołu nadpobudliwości psychoruchowej z deficytem uwagi (ADHD) - Google Patents

Wielowarstwowa tabletka mazindol IR/SR i jej zastosowanie w leczeniu zespołu nadpobudliwości psychoruchowej z deficytem uwagi (ADHD)

Info

Publication number
PL3426232T3
PL3426232T3 PL17724102T PL17724102T PL3426232T3 PL 3426232 T3 PL3426232 T3 PL 3426232T3 PL 17724102 T PL17724102 T PL 17724102T PL 17724102 T PL17724102 T PL 17724102T PL 3426232 T3 PL3426232 T3 PL 3426232T3
Authority
PL
Poland
Prior art keywords
mazindol
adhd
treatment
attention deficit
hyperactivity disorder
Prior art date
Application number
PL17724102T
Other languages
English (en)
Inventor
Alexander C. Zwyer
Lewis P. Amsel
Virginia SCHMITH
Scott BRANTLEY
Original Assignee
Nls Pharmaceutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/055048 external-priority patent/WO2017152974A1/en
Application filed by Nls Pharmaceutics Ag filed Critical Nls Pharmaceutics Ag
Publication of PL3426232T3 publication Critical patent/PL3426232T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
PL17724102T 2016-03-09 2017-03-08 Wielowarstwowa tabletka mazindol IR/SR i jej zastosowanie w leczeniu zespołu nadpobudliwości psychoruchowej z deficytem uwagi (ADHD) PL3426232T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662305600P 2016-03-09 2016-03-09
PCT/EP2016/055048 WO2017152974A1 (en) 2016-03-09 2016-03-09 A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
PCT/IB2017/000352 WO2017153846A2 (en) 2016-03-09 2017-03-08 A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
EP17724102.3A EP3426232B1 (en) 2016-03-09 2017-03-08 A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)

Publications (1)

Publication Number Publication Date
PL3426232T3 true PL3426232T3 (pl) 2022-01-10

Family

ID=58710015

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17724102T PL3426232T3 (pl) 2016-03-09 2017-03-08 Wielowarstwowa tabletka mazindol IR/SR i jej zastosowanie w leczeniu zespołu nadpobudliwości psychoruchowej z deficytem uwagi (ADHD)

Country Status (16)

Country Link
US (2) US11207271B2 (pl)
EP (2) EP3426232B1 (pl)
JP (2) JP7127832B2 (pl)
KR (1) KR102304743B1 (pl)
CN (2) CN109152740A (pl)
AU (2) AU2017230974B2 (pl)
BR (1) BR112018068143A2 (pl)
CA (1) CA3016852C (pl)
ES (1) ES2884973T3 (pl)
IL (2) IL261418B (pl)
MA (2) MA45840A (pl)
MX (1) MX2018010864A (pl)
NZ (1) NZ745921A (pl)
PL (1) PL3426232T3 (pl)
PT (1) PT3426232T (pl)
WO (1) WO2017153846A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10363220B2 (en) 2015-06-03 2019-07-30 Triastek, Inc. Compartmented pharmaceutical dosage forms
JP2020533295A (ja) 2017-09-07 2020-11-19 エヌエルエス−１ ファルマ アーゲー ヘロイン依存症及び物質使用障害のためのマジンドール治療
CN116270513A (zh) 2018-01-09 2023-06-23 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855440A (en) 1988-02-16 1989-08-08 Sherex Chemical Company, Inc. Method for producing stabilized imidazoline derivatives
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
JP2001102172A (ja) 1999-09-30 2001-04-13 Idemitsu Kosan Co Ltd 有機エレクトロルミネッセンス素子
GB0009522D0 (en) 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
JP2004520275A (ja) 2000-11-10 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー 加水分解的に不安定な組成物
CN1579401A (zh) 2003-08-11 2005-02-16 李亦武 一种止咳平喘药物新剂型及制备方法
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
CN1593404A (zh) 2004-07-16 2005-03-16 南京亿华药业有限公司 甲硝唑双层叠合缓释片及其制备方法
CA2590802A1 (en) 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
PT1954241E (pt) * 2005-11-28 2012-06-01 Orexigen Therapeutics Inc Formulação de zonisamida de libertação sustentada
KR100752417B1 (ko) 2006-02-14 2007-08-28 대원제약주식회사 안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
FR2899476B1 (fr) 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
CN1985823A (zh) 2006-11-21 2007-06-27 北京润德康医药技术有限公司 一种含有盐酸二甲双胍罗格列酮的缓释制剂及其制备方法
CA2905541C (en) * 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US20090318520A1 (en) * 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
AU2011235221B2 (en) * 2010-03-31 2015-10-01 Supernus Pharmaceuticals, Inc. Formulations of mazindol
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders

Also Published As

Publication number Publication date
BR112018068143A2 (pt) 2019-07-30
IL261418B (en) 2022-09-01
CA3016852C (en) 2021-03-23
AU2017230974A1 (en) 2018-09-20
CA3016852A1 (en) 2017-09-14
CN116803379A (zh) 2023-09-26
US11207271B2 (en) 2021-12-28
EP3426232A2 (en) 2019-01-16
WO2017153846A2 (en) 2017-09-14
JP2019507771A (ja) 2019-03-22
KR20190019044A (ko) 2019-02-26
WO2017153846A3 (en) 2017-10-12
MA55045A (fr) 2021-12-29
AU2017230974B2 (en) 2022-02-03
EP3426232B1 (en) 2021-06-02
US20220160639A1 (en) 2022-05-26
JP2022160647A (ja) 2022-10-19
CN109152740A (zh) 2019-01-04
MX2018010864A (es) 2019-03-28
US20210038521A1 (en) 2021-02-11
ES2884973T3 (es) 2021-12-13
MA45840A (fr) 2021-05-05
KR102304743B1 (ko) 2021-09-24
EP3928770A1 (en) 2021-12-29
IL261418A (en) 2018-10-31
PT3426232T (pt) 2021-08-31
JP7127832B2 (ja) 2022-08-30
AU2022202771A1 (en) 2022-05-19
NZ745921A (en) 2021-12-24
IL295519A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
HK1249103B (zh) 多環氨甲醯基吡啶酮化合物及其藥物用途
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL261418A (en) Mazindol immediate-release/delayed-release multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder
HUE051059T2 (hu) Rák és diabétesz kezelésére szolgáló 6-heterociklusos-4-morfolin-4-ilpiridin-2-on vegyületek
EP3536775A4 (en) REACTION TREATMENT CONTAINER AND REACTION TREATMENT DEVICE
PT3416945T (pt) Compostos de 6-aril-4-(morfolin-4-il)-1h-piridina-2-ona úteis para o tratamento do cancro e da diabetes
EP3253715A4 (en) Improved fluid treatment apparatus and processes
GB201601865D0 (en) Oral dosage products and processes
SG11201705934UA (en) Substrate treatment apparatus and reaction tube
IL251940A0 (en) Dihydropyrimidin-2-one compounds and their medical use
PL3316867T3 (pl) Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
PL3700486T3 (pl) Aparat do obracania pacjenta
ZA201806777B (en) Fluid treatment process
SG10201405254TA (en) Process Tray and Treatment Apparatus Using the Same
IL252493B (en) Compounds for use in the prevention or treatment of cancer
GB201610194D0 (en) Titanium dioxide product
EP2960407A4 (en) LOCK ENTRY UNIT AND CONVERSION APPARATUS
LT3548006T (lt) Kompozicija, skirta žarnyno pakitimams gydyti
GB201601514D0 (en) New processes and compounds
PL3185855T3 (pl) Tabletka powlekana filmem do leczenia ostrego bólu
GB201604896D0 (en) A hyperbaric treatment apparatus
ZAF201600608S (en) Paediatric hospital bed
ZAF201600610S (en) Paediatric hospital bed
GB201621274D0 (en) New processes and compounds
GB201609555D0 (en) Carbon dioxide plasma treatment